INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Story continues below

The disclosure under Item 8.01 of this current report on Form8-K is incorporated by reference.

Item 8.01. Other Events.

On January9, 2018, the Board of Directors of Innoviva,Inc. (the “Company”) approved the extension of the deadline for stockholders to nominate directors and to propose other business to be considered at the Company’s 2018 annual meeting of stockholders (the “2018 Annual Meeting”) from February4, 2018 to February19, 2018. Any director nominations or proposals of other business received by the Company prior to the close of business on February19, 2018, and otherwise complying with the Company’s Amended and Restated Bylaws, will be considered timely. This waiver and extension of the advance notice deadline is applicable only for the 2018 Annual Meeting.


About INNOVIVA,INC. (NASDAQ:INVA)

Innoviva, Inc., formerly Theravance, Inc., focuses on bringing new medicines to patients in areas of unmet need. The Company is engaged in the development, commercialization and financial management of bio-pharmaceuticals. Its portfolio focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol (FF/VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). It operates in providing capital return to stockholders by maximizing the potential value of its respiratory assets partnered with GSK segment. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of VI, a LABA and FF, an inhaled corticosteroid (FF/VI) delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of UMEC, a long-acting muscarinic antagonist (LAMA) and VI, a LABA for the treatment of chronic obstructive pulmonary diseases (COPD).

An ad to help with our costs